IPCIF Stock
Price Chart
IPCIF Financial and Trading Overview
| stock price | 0.15 |
| Previous Close | 0.04 |
| Open | 0.06 |
| Bid | 0 x 0 |
| Ask | 0 x 0 |
| Day's Range | 0.06 - 0.06 |
| 52 Week Range | 0.01 - 0.11 |
| Volume | 1.04K |
| Avg. Volume | 5.23K |
| Market Cap | 2.13M |
| Beta (5Y Monthly) | 0.997113 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IPCIF Valuation Measures
| Enterprise Value | 3.62M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.915616 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 11.725 |
| Enterprise Value/EBITDA | -1.656 |
Trading Information
Stock Price History
| Beta (5Y Monthly) | 0.997113 |
| 52-Week Change | -45.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.11 |
| 52 Week Low | 0.01 |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.07 |
IPCIF Share Statistics
| Avg. Volume (3 month) | 5.23K |
| Avg. Daily Volume (10-Days) | 8.75K |
| Shares Outstanding | 33.09M |
| Float | 28.84M |
| Short Ratio | 0.39 |
| % Held by Insiders | 1.76% |
| % Held by Institutions | 11.09% |
| Shares Short | 714K |
| Short % of Float | 3.35% |
| Short % of Shares Outstanding | 3.25% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | November 30, 2022 |
| Most Recent Quarter (mrq) | February 28, 2023 |
| Next Fiscal Year End | November 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -770.74% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -85.33% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 308.66K |
| Revenue Per Share (ttm) | 0.009 |
| Quarterly Revenue Growth (yoy) | 291.19% |
| Gross Profit (ttm) | 65.73K |
| EBITDA | -2184783 |
| Net Income Avi to Common (ttm) | -2367160 |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 69.55K |
| Total Cash Per Share (mrq) | 0.002 |
| Total Debt (mrq) | 2.3M |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.059 |
| Book Value Per Share (mrq) | -0.33 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -841818 |
| Levered Free Cash Flow (ttm) | -101801 |
Profile of
| Country | United States |
| State | ON |
| City | Toronto |
| Address | 30 Worcester Road |
| ZIP | M9W 5X2 |
| Phone | 416 798 3001 |
| Website | https://www.intellipharmaceutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
Q&A For Stock
What is a current IPCIF stock price?
IPCIF stock price today per share is 0.15 .
How to purchase stock?
You can buy IPCIF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ?
The stock symbol or ticker of is IPCIF.
Which industry does the company belong to?
The industry is Biotechnology.
How many shares does have in circulation?
The max supply of shares is 0.
What is Price to Earnings Ratio (PE Ratio)?
PE Ratio is 0.00000000 now.
What was earnings per share over the trailing 12 months (TTM)?
EPS is 0 over the trailing 12 months.
Which sector does the company belong to?
The sector is Healthcare.